RADIOLABELED MONOCLONAL ANTIBODY IMAGING OF TUMORS AND POSITRON EMISSION TOMOGRAP

这些研究旨在开发检测和治疗恶性肿瘤的改进方法。我们的团队在国立癌症研究所的各个实验室进行初步筛选后，对似乎有希望的抗体进行临床前评估，并开发这些抗体用于临床应用。本课题组进行了药代动力学和剂量学的临床试验。与Waldmann博士（主要研究者）合作的放射免疫治疗试验正在进行中，我们使用了人源化抗tac单克隆抗体。正在进行影像学研究，比较Tc-99 m抗CEA Fab（FDA批准）和F-18脱氧葡萄糖在既往有结直肠癌病史且CEA升高而无常规放射学检查疾病证据的患者中的使用。我们已经表征了α发射标记抗体一旦发生调节和内化的命运，作为其临床前评价的一部分。我们已经开始初步研究评估肿瘤治疗的抗体预靶向。

These studies are designed to develop improved methods for detect-ing and treating malignancies. Our group performs preclinical evaluation of antibodies that appear to be promising after initial screening by various laboratories at the National Cancer Institute and develops these antibodies for clinical application. The clinical trials evaluating their pharmacokinetics and dosimetry are performed by our group. A collaborative radioimmunotherapy trial with Dr. Waldmann (Principal Investigator) in which we used humanized anti-tac monoclonal antibody, is ongoing. Imaging studies comparing the use of Tc-99m anti- CEA Fab (FDA approved) and F-18 deoxyglucose in patients with previous history of colorectal carcinoma and rising CEA with-out evidence of disease by conventional radiographic modalities are ongoing. We have characterized the fate of alpha emitting labeled antibody once modulation and internalization occur, as part of their preclinical evaluation. We have begun preliminary studies evaluating pretargeting of antibodies for tumor therapy.